BRAF V600E Mutations In Papillary Thyroid Carcinoma

Bezmialem Vakif University

Status and phase: Unknown; Early Phase 1

Conditions: Papillary Thyroid Carcinoma

Treatments: Genetic: BRAF V600E POSITIVITY

Study type: Interventional

Funder types: Other

Identifiers

NCT01417442

2011/5

Details and patient eligibility

About

The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.

Full description

Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.

Enrollment: 150 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with papillary thyroid cancer

Exclusion criteria

• Patients who do not want to be a part of this study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

BRAF V600E POSITIVITY

Experimental group

Description:

This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.

Treatment:

Genetic: BRAF V600E POSITIVITY